Navigation Links
RECITAL Study Presents Excellent Outcomes and Rapid Patient Recovery With Revolutionary Femoral Access Procedure
Date:12/1/2011

REDWOOD CITY, Calif., Dec. 1, 2011 /PRNewswire/ -- Clinical Investigators for Arstasis, Inc., reported the results of the RECITAL study during the recent TCT Meeting in San Francisco, demonstrating the Arstasis access device enables rapid, secure, implant-free closure of femoral arteries after cardiac catheterization procedures. The device creates a unique access pathway, called an Arstaotomy, into the femoral artery through which catheterization procedures are performed.

RECITAL is a prospective, multi-center clinical study that enrolled 351 patients to assess device and procedural success of key post-catheterization recovery measures that influence the safety and speed toward discharging those patients from the hospital. The results indicate that hospitals may be able to both reduce current complication rates and eliminate costs from longer hospitalizations in this patient population.

Key results of the RECITAL study showed that device deployment was successful in 97% of RECITAL patients and femoral bleeding stopped after only 3 minutes for diagnostic angiogram patients and 5 minutes for anti-coagulated patients undergoing a percutaneous coronary intervention (PCI). Most of the patients were able to sit up within 15-30 minutes and were able to walk in about one hour after an angiogram and two hours after a PCI. Investigators found no major complications related to use of the Arstasis device.

Dr. Dale Wortham, University of Tennessee  Medical Center, Knoxville and RECITAL Study Principal Investigator, commented, "Introducing foreign materials in a patient to close the femoral artery can be problematic. We were very pleased the RECITAL Study demonstrated the Arstaotomy procedure can deliver closure-like hemostasis and ambulation times without the use of a temporary or permanent implant."

The RECITAL Study illustrates the Arstaotomy procedure can potentially accelerate patient throughput, delivering a quicker, m
'/>"/>

SOURCE Arstasis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome
2. Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinsons Disease
3. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
4. BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA
5. New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System
6. Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
7. Cara Therapeutics Initiates Phase I Study with Oral Formulation of Novel Peripherally-Acting Kappa Opioid Agonist
8. Updated Survival Data from Study Comparing TTF™ (Tumor Treating Fields) Therapy to Best Standard Chemotherapy for Recurrent Glioblastoma Reported at the 16th Annual Scientific Meeting of the Society for NeuroOncology
9. Perceptive Informatics® Global Survey Results Indicate Wide Use of Industry-Standard Medical Imaging Metrics to Meet Study Milestones
10. Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
11. goBalto Sponsors Tufts CSDD Study to Benchmark the Clinical Trial Initiation Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014  ConvaTec, a privately-held medical products and technologies ... been appointed chief financial officer of the company, effective ... executive vice president and chief financial officer of Elan ... Mr. Clerkin was part of a senior team that ... its sale to Perrigo, a pharmaceutical manufacturer, in December ...
(Date:7/22/2014)... , July 22, 2014  According to the American ... children spend on digital devices. An AOA survey reports ... 10 and 17 estimate they use an electronic device ... separate AOA survey of parents revealed that only 40 ... device for that same amount of time. Eye doctors ...
(Date:7/22/2014)... , July 22, 2014  NeuroSigma, Inc. (NeuroSigma), ... focused on commercialization of its non-invasive Monarch ... and neuropsychiatric disorders, today announced that enrollment has begun ... nerve stimulation (eTNS) as adjunctive therapy for the treatment ... being conducted at the Olive View-UCLA Medical Center in ...
Breaking Medicine Technology:ConvaTec Names Nigel Clerkin Chief Financial Officer 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5
... Infection Prevention Professionals With Guidelines,and Tools, ... Association for,Professionals in Infection Control and ... new educational initiatives aimed at eliminating,healthcare-associated ... and the three infections that the ...
... Innocoll, Inc., a privately-held,specialty pharmaceutical company, announced ... clinical trials sponsored by its wholly owned ... TOPICAL for the,treatment and prevention of infected ... GENTAMICIN TOPICAL is a biodegradable and fully ...
Cached Medicine Technology:APIC Launches 'Targeting Zero' Initiative to Eradicate C. Difficile and Infections Deemed Preventable By CMS 2APIC Launches 'Targeting Zero' Initiative to Eradicate C. Difficile and Infections Deemed Preventable By CMS 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers 4
(Date:7/22/2014)... Today, Therapy Changes announces the start of their Teen ... help increase their knowledge and ability to cope with life’s ... to make healthy and positive decisions while connecting with like-minded ... but also a time of major life transition and stress,” ... . , “Teens can at times feel misunderstood, so rather ...
(Date:7/22/2014)... Quebec (PRWEB) July 22, 2014 ... is a set of simple tools, designed to help ... have little or no experience with biofeedback. The tools ... stressful situations and elucidate any abnormal patterns to teach ... today’s fast paced world, we are familiar with stress ...
(Date:7/22/2014)... Mass. (PRWEB) July 22, 2014 ... EBSCO Information Services , announces the launch ... assist occupational health and safety professionals employed by ... chemicals and need to manage the impact of ... PoisonEXPERT provides access to relevant chemical-specific information and ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 The Muscular Dystrophy ... the third annual MUSCLE UP campaign that will ... more than one million Americans fighting muscle disease. ... to visit participating Jiffy Lube service centers through Sept. 1, ... to continue to make progress in the fight for muscle ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Brand ... landed MediaSource as a Ragan Communications 2014 Health ... will be the second consecutive year that MediaSource placed ... which was awarded to the winning MediaSource team last ... to keep this title against three other contenders that ...
Breaking Medicine News(10 mins):Health News:Therapy Changes Announces Teen Support Group Therapy 2Health News:Thought Technology to Present Software for Stress Control at the 2014 American Psychological Association Convention in DC 2Health News:Thought Technology to Present Software for Stress Control at the 2014 American Psychological Association Convention in DC 3Health News:PoisonEXPERT™ from ExPub Now Available 2Health News:PoisonEXPERT™ from ExPub Now Available 3Health News:Jiffy Lube® Supports Fight Against Muscle Disease with Third Annual MUSCLE UP® Campaign 2Health News:Jiffy Lube® Supports Fight Against Muscle Disease with Third Annual MUSCLE UP® Campaign 3Health News:MediaSource Brand Journalism Returns to Best Health Care Agency Competition in Ragan Communications Health Care Awards 2Health News:MediaSource Brand Journalism Returns to Best Health Care Agency Competition in Ragan Communications Health Care Awards 3
... to Serve Elective Cash Pay ... ... financial services for elective (cash pay) surgery, today,announced a leap forward in ... for bariatric surgeons, cash pay business.,Beginning July 1st, 2008, the BLISCare(SM) insurance ...
... chemotherapeutic agents remains a large problem. In some cases, ... cellular process known as translation, which is central to ... Pelletier and colleagues, at McGill University, Montreal, have identified ... cancer cells to standard anticancer chemotherapeutic agents. , In ...
... a healthier life, study finds , , THURSDAY, June 12 ... aging, a new study found. , Researchers at the ... 60 and older for use of sleeping aids, daytime ... quality, and sleep duration. Based on the results, 20.8 ...
... FDA on food safety , , THURSDAY, June 12 (HealthDay ... ongoing outbreak of salmonella-contaminated tomatoes has risen to 228 ... reported Thursday. , Also Thursday, Congressional investigators said the ... its own stated goals of protecting the nation,s food ...
... Pa., June 12 MEDRAD, INC., has ... PETNET Solutions,a fully owned subsidiary of Siemens ... health care providers to inject Fluorodeoxyglucose,(FDG) for ... an innovative, new way. The partnership will ...
... of Excellence (CCE), the,nation,s only practice-owned and physician ... slate and Board of Directors.,Effective immediately, J. Ike ... the interim President of CCE. In addition, Linda,Bosserman, ... Medical,Officer. Dr. Bosserman had previously served as CCE,s ...
Cached Medicine News:Health News:BLIS to Offer Coverage Through 'A' Rated Insurance Carrier 2Health News:BLIS to Offer Coverage Through 'A' Rated Insurance Carrier 3Health News:Better Sleepers Are 'Successful Agers' 2Health News:228 People in 22 States Sickened in Ongoing Salmonella-Tomato Outbreak 2Health News:228 People in 22 States Sickened in Ongoing Salmonella-Tomato Outbreak 3Health News:228 People in 22 States Sickened in Ongoing Salmonella-Tomato Outbreak 4Health News:228 People in 22 States Sickened in Ongoing Salmonella-Tomato Outbreak 5Health News:MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery 2Health News:MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery 3Health News:Cancer Clinics of Excellence (CCE) Announces Management and Board of Directors Slate at 1st Annual General Membership Meeting 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: